Compass Pathways: Still A Buy, But The Exit Just Got Complicated

Compass Pathways stays a Buy, but Eli Lilly’s AtaiBeckley deal raises competition and funding risks. Click to get key ...
Seeking Alpha

Compass Pathways: Red Hot Psychedelic Market For Pioneer With Near Term Psychedelic Filing In TRD

Compass Pathways plc (CMPS) has faced significant risks since my last 'Buy' rating in January 2026. CMPS shares had declined approximately 10% over the intervening months, but then registered huge ...